TFF Pharmaceuticals, Inc. Common Stock
TFFP
TFFP was delisted on the 12th of December, 2024.
51 hedge funds and large institutions have $41M invested in TFF Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 13 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
6% less funds holding
Funds holding: 54 → 51 (-3)
9% less capital invested
Capital invested by funds: $45.1M → $41M (-$4.17M)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
59% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $2.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.42M |
| 2 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$490K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$397K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$367K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$361K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$7.87M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.09M |
| 3 |
Renaissance Technologies
New York
|
-$672K |
| 4 |
ACA
Apis Capital Advisors
New York
|
-$618K |
| 5 |
Millennium Management
New York
|
-$404K |
TFFP Hedge Fund Activity: Q4 2021 in Review
51 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in TFF Pharmaceuticals, Inc. Common Stock (TFFP) for Q4 2021, worth a combined $41M — down 9.2% from $45.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TFFP and 10 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 17 added.
The largest buyer was Susquehanna International Group, adding an estimated $1.42M. The largest seller was Corriente Advisors, exiting entirely with an estimated $7.87M sold.
- 51 institutional investors held TFF Pharmaceuticals, Inc. Common Stock (TFFP) as of Q4 2021, down from 54 in Q3 2021.
- Funds reported $41M of TFF Pharmaceuticals, Inc. Common Stock stock for Q4 2021, down 9.2% quarter-over-quarter.
- 10 funds opened new TFF Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 13 closed out, a net change of -3 holders.
- The largest TFF Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Susquehanna International Group, an estimated $1.42M added.
- The largest TFF Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was Corriente Advisors, an estimated $7.87M sold.
Based on aggregated 13F filings for Q4 2021.